Donate

medical_news_banner.jpg

Per an early release of the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR), new information was released today regarding Eculizumab (Soliris®) in patients with the rare blood disorders, paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Read the MMWR article in full here.

 

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.